Details of the Drug
General Information of Drug (ID: DMGQVF5)
| Drug Name |
2,5-Dideoxy-2,5-imino-D-mannitol
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
59920-31-9; (2R,3R,4R,5R)-2,5-bis(hydroxymethyl)pyrrolidine-3,4-diol; 2,5-Dihydroxymethyl-3,4-dihydroxypyrrolidine; CHEBI:4289; CHEMBL312653; NSC624987; NSC613239; 2(r),5(r)-bis(hydroxymethyl)-3(r),4(r)-dihydroxypyrrolidine; 2,5-Anhydro-2,5-imino-D-mannitol; DQQ; 2,5-dideoxy-2,5-imino-L-mannitol; NSC 624987; AC1L3YWM; AC1Q59GS; SCHEMBL466574; ZINC1492230; 2,5-Pyrrolidinedimethanol, 3,4-dihydroxy-, (2R,3R,4R,5R)-
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 163.17 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -1.8 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 5 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


